期刊论文详细信息
Allergy, Asthma & Clinical Immunology
Ingestion of milk containing the Dp2 peptide, a dust mite allergen, protects mice from allergic airway inflammation and hyper-responsiveness
Hsu-Chung Liu2  Shun-Yuan Pai1  Winston TK Cheng5  Hsiao-Ling Chen4  Tung-Chou Tsai1  Shang-Hsun Yang3  Chuan-Mu Chen6 
[1] Department of Life Sciences, Agricultural Biotechnology Center, National Chung Hsing University, Kuo Kuang Rd, Taichung, 402, Taiwan
[2] Division of Chest Medicine, Department of Internal Medicine, Chung Shan Medical University Hospital and School of Medicine, Chung Shan Medical University, Taichung, Taiwan
[3] Department of Physiology, National Cheng Kung University, Tainan, Taiwan
[4] Department of Bioresources, Da-Yeh University, Changhwa, Taiwan
[5] Department of Animal Science and Biotechnology, Tunghai University, Taichung, Taiwan
[6] iEGG Center, National Chung Hsing University, Taichung, Taiwan
关键词: Tolerance;    Group 2 allergen of Dermatophagoides pteronyssinus;    Immunotherapy;    Asthma;    Allergen;    Transgenic mice;   
Others  :  792256
DOI  :  10.1186/1710-1492-9-21
 received in 2013-04-14, accepted in 2013-06-05,  发布年份 2013
PDF
【 摘 要 】

Background

Allergen-specific immunotherapy has been demonstrated to have potential for the treatment of allergic diseases. Transgenic animals are currently the best available bioreactors to produce recombinant proteins, which can be secreted in milk. It has not been clearly demonstrated whether milk from transgenic animals expressing recombinant allergens has immunomodulatory effects on allergic asthma.

Methods

We aimed to determine whether the oral administration of milk containing a mite allergen can down-regulate allergen-specific airway inflammation. Transgenic CD-1 mice that express a recombinant group 2 allergen from Dermatophagoides pteronyssinus (Dp2) in their milk were generated using an embryonic gene-microinjection technique. Mouse pups were fed transgenic Dp2-containing milk or wild-type milk. Subsequently, these mice were sensitized and challenged with Dp2 to induce allergic airway inflammation.

Results

Upon sensitization and challenge, mice fed transgenic Dp2 milk had decreased T-helper 2 (Th2) and increased T-helper 1 (Th1) responses in the airway compared with mice fed wild-type milk. Moreover, pre-treatment with transgenic Dp2 milk attenuated airway inflammation and decreased airway hyper-responsiveness.

Conclusions

This study provides new evidence that oral administration of transgenic milk containing the Dp2 allergen down-regulated and moderately protected against allergic airway inflammation. Milk from transgenic animals expressing allergens may have potential use in the prevention of allergic asthma.

【 授权许可】

   
2013 Liu et al.; licensee BioMed Central Ltd.

【 预 览 】
附件列表
Files Size Format View
20140705025416317.pdf 3796KB PDF download
Figure 7. 100KB Image download
Figure 6. 115KB Image download
Figure 5. 235KB Image download
Figure 4. 38KB Image download
Figure 3. 71KB Image download
Figure 2. 170KB Image download
Figure 1. 97KB Image download
【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

Figure 6.

Figure 7.

【 参考文献 】
  • [1]Sporik R, Chapman MD, Platts-Mills TA: House dust mite exposure as a cause of asthma. Clin Exp Allergy 1992, 22:897-906.
  • [2]Thomas WR: Mite allergens groups I-VII. A catalogue of enzymes. Clin Exp Allergy 1993, 23:350-3.
  • [3]Chang YC, Hsieh KH: The study of house dust mites in Taiwan. Ann Allergy 1989, 62:101-6.
  • [4]Chua KY, Doyle CR, Simpson RJ, Turner KJ, Stewart GA, Thomas WR: Isolation of cDNA coding for the major mite allergen Der p II by IgE plaque immunoassay. Int Arch Allergy Appl Immunol 1990, 91:118-23.
  • [5]Nagata M, Nakagome K: Allergen immunotherapy in asthma: current status and future perspectives. Allergol Int 2010, 59:15-9.
  • [6]O’Hehir RE, Gardner LM, de Leon MP, Hales BJ, Biondo M, Douglass JA, Rolland JM, Sandrini A: House dust mite sublingual immunotherapy: the role for transforming growth factor-beta and functional regulatory T cells. Am J Respir Crit Care Med 2009, 180:936-47.
  • [7]Polosa R, Al-Delaimy WK, Russo C, Piccillo G, Sarva M: Greater risk of incident asthma cases in adults with allergic rhinitis and effect of allergen immunotherapy: a retrospective cohort study. Respir Res 2005, 6:153. BioMed Central Full Text
  • [8]Niggemann B, Jacobsen L, Dreborg S, Ferdousi HA, Halken S, Host A, Koivikko A, Koller D, Norberg LA, Urbanek R, Valovirta E, Wahn U, Moller C: Five-year follow-up on the PAT study: specific immunotherapy and long-termprevention of asthma in children. Allergy 2006, 61:855-9.
  • [9]Williams AP, Krishna MT, Frew AJ: The safety of immunotherapy. Clin Exp Allergy 2004, 34:513-4.
  • [10]Novembre E, Galli E, Landi F, Caffarelli C, Pifferi M, De Marco E, Burastero SE, Calori G, Benetti L, Bonazza P, Puccinelli P, Parmiani S, Bernardini R, Vierucci A: Coseasonal sublingual immunotherapy reduces the development of asthma in children with allergic rhinoconjunctivitis. J Allergy Clin Immunol 2004, 114:851-7.
  • [11]Valovirta E, Jacobsen L, Ljorring C, Koivikko A, Savolainen J: Clinical efficacy and safety of sublingual immunotherapy with tree pollen extract in children. Allergy 2006, 61:1177-83.
  • [12]Burks AW, Laubach S, Jones SM: Oral tolerance, food allergy, and immunotherapy: implications for future treatment. J Allergy Clin Immunol 2008, 121:1344-50.
  • [13]Pauli G, Larsen TH, Rak S, Horak F, Pastorello E, Valenta R, Purohit A, Arvidsson M, Kavina A, Schroeder JW, Mothes N, Spitzauer S, Montagut A, Galvain S, Melac M, Andre C, Poulsen LK, Malling HJ: Efficacy of recombinant birch pollen vaccine for the treatment of birch-allergic rhinoconjunctivitis. J Allergy Clin Immunol 2008, 122:951-60.
  • [14]Purohit A, Niederberger V, Kronqvist M, Horak F, Gronneberg R, Suck R, Weber B, Fiebig H, van Hage M, Pauli G, Valenta R, Cromwell O: Clinical effects of immunotherapy with genetically modified recombinant birch pollen Bet v 1 derivatives. Clin Exp Allergy 2008, 38:1514-25.
  • [15]Chen HL, Wang LC, Chang CH, Yen CC, Cheng WT, Wu SC, Hung CM, Kuo MF, Chen CM: Recombinant porcine lactoferrin expressed in the milk of transgenic mice protects neonatal mice from a lethal challenge with enterovirus type 71. Vaccine 2008, 26:891-8.
  • [16]Chen HL, Huang JY, Chu TW, Tsai TC, Hung CM, Lin CC, Liu FC, Wang LC, Chen YJ, Lin MF, Chen CM: Expression of VP1 protein in the milk of transgenic mice: a potential oral vaccine protects against enterovirus 71 infection. Vaccine 2008, 26:2882-9.
  • [17]Chen CM, Wang CH, Wu SC, Lin CC, Lin SH, Cheng WT: Temporal and spatial expression of biologically active human factor VIII in the milk of transgenic mice driven by mammary-specific bovine alpha-lactalbumin regulation sequences. Transgenic Res 2002, 11:257-68.
  • [18]Tung YT, Chen HL, Lai CW, Shen CJ, Lai YW, Chen CM: Curcumin reduces pulmonary tumorigenesis in vascular endothelial growth factor (VEGF)-overexpressing transgenic mice. Mol Nutri Food Res 2011, 55:1036-43.
  • [19]Yen CC, Lin CY, Chong KY, Tsai TC, Shen CJ, Lin MF, Su CY, Chen HL, Chen CM: Lactoferrin as a natural regimen of selective decontamination of the digestive tract: recombinant porcine lactoferrin expressed in the milk of transgenic mice protects neonates from pathogen challenges in the gastrointestinal tract. J Infect Dis 2009, 199:590-8.
  • [20]Chen CM, Chen HL, Hsiau THC, Hsiau AH, Shi H, Brock GJ, Wei SH, Caldwell CW, Yan PS, Huang TH: Methylation target array for rapid analysis of CpG island hypermethylation in multiple tissue genomes. Am J Pathol 2003, 163:37-45.
  • [21]Chen YJ, Wu CY, Chang CC, Ma CJ, Li MC, Chen CM: Nuclear Kruppel-like factor 4 expression is associated with human skin squamous cell carcinoma progression and metastasis. Cancer Biol Ther 2008, 7:777-82.
  • [22]Hamelmann E, Schwarze J, Takeda K, Oshiba A, Larsen GL, Irvin CG, Gelfand EW: Noninvasive measurement of airway responsiveness in allergic mice using barometric plethysmography. Am J Respir Crit Care Med 1997, 156:766-75.
  • [23]Yen CC, Lai YW, Chen HL, Lai CW, Lin CY, Chen W, Kuan YP, Hsu WH, Chen CM: Aerosolized human extracellular superoxide dismutase prevents hyperoxia-induced lung injury. PLoS One 2011, 6:e26870.
  • [24]Verhasselt V, Milcent V, Cazareth J, Kanda A, Fleury S, Dombrowicz D, Glaichenhaus N, Julia V: Breast milk-mediated transfer of an antigen induces tolerance and protection from allergic asthma. Nat Med 2008, 14:170-5.
  • [25]Hsu CH, Lin SS, Liu FL, Su WC, Yeh SD: Oral administration of a mite allergen expressed by zucchini yellow mosaic virus in cucurbit species downregulates allergen-induced airway inflammation and IgE synthesis. J Allergy Clin Immunol 2004, 113:1079-85.
  • [26]Verhasselt V: Neonatal tolerance under breastfeeding influence. Curr Opin Immunol 2010, 22:623-30.
  • [27]Mosconi E, Rekima A, Seitz-Polski B, Kanda A, Fleury S, Tissandie E, Monteiro R, Dombrowicz DD, Julia V, Glaichenhaus N, Verhasselt V: Breast milk immune complexes are potent inducers of oral tolerance in neonates and prevent asthma development. Mucosal Immunol 2010, 3:461-74.
  • [28]Drachenberg KJ, Wheeler AW, Stuebner P, Horak F: A well-tolerated grass pollen-specific allergy vaccine containing a novel adjuvant, monophosphoryl lipid A, reduces allergic symptoms after only four preseasonal injections. Allergy 2001, 56:498-505.
  • [29]Tulic MK, Fiset PO, Christodoulopoulos P, Vaillancourt P, Desrosiers M, Lavigne F, Eiden J, Hamid Q: Amb a 1-immunostimulatory oligodeoxynucleotide conjugate immunotherapy decreases the nasal inflammatory response. J Allergy Clin Immunol 2004, 113:235-41.
  • [30]Creticos PS, Schroeder JT, Hamilton RG, Balcer-Whaley SL, Khattignavong AP, Lindblad R, Li H, Coffman R, Seyfert V, Eiden JJ, Broide D: Immunotherapy with a ragweed-toll-like receptor 9 agonist vaccine for allergic rhinitis. N Engl J Med 2006, 355:1445-55.
  • [31]Houdebine LM: Transgenic animal bioreactors. Transgenic Res 2000, 9:305-20.
  • [32]Houdebine LM: Production of pharmaceutical proteins by transgenic animals. Comp Immunol Microbiol Infect Dis 2009, 32:107-21.
  • [33]Zinovieva N, Lassnig C, Schams D, Besenfelder U, Wolf E, Muller S, Frenyo L, Seregi J, Muller M, Brem G: Stable production of human insulin-like growth factor 1 (IGF-1) in the milk of hemi- and homozygous transgenic rabbits over several generations. Transgenic Res 1998, 7:437-47.
  • [34]Devinoy E, Thepot D, Stinnakre MG, Fontaine ML, Grabowski H, Puissant C, Pavirani A, Houdebine LM: High level production of human growth hormone in the milk of transgenic mice: the upstream region of the rabbit whey acidic protein (WAP) gene targets transgene expression to the mammary gland. Transgenic Res 1994, 3:79-89.
  • [35]Ebert KM, Selgrath JP, DiTullio P, Denman J, Smith TE, Memon MA, Schindler JE, Monastersky GM, Vitale JA, Gordon K: Transgenic production of a variant of human tissue-type plasminogen activator in goat milk: generation of transgenic goats and analysis of expression. Biotechnol NY 1991, 9:835-838.
  • [36]Kuroiwa Y, Kasinathan P, Choi YJ, Naeem R, Tomizuka K, Sullivan EJ, Knott JG, Duteau A, Goldsby RA, Osborne BA, Ishida I, Robl JM: Cloned transchromosomic calves producing human immunoglobulin. Nat Biotechnol 2002, 20:889-94.
  • [37]van Berkel PH, Welling MM, Geerts M, van Veen HA, Ravensbergen B, Salaheddine M, Pauwels EK, Pieper F, Nuijens JH, Nibbering PH: Large scale production of recombinant human lactoferrin in the milk of transgenic cows. Nat Biotechnol 2002, 20:484-7.
  • [38]Adiguzel C, Iqbal O, Demir M, Fareed J: European community and US-FDA approval of recombinant human antithrombin produced in genetically altered goats. Clin Appl Thromb Hemost 2009, 15:645-51.
  文献评价指标  
  下载次数:99次 浏览次数:15次